COX-2 inhibitors: a role in colorectal cancer?
Otten
N
N
The Canadian Coordinating Office for Health Technology Assessment, Canada. nicko@ccohta.ca
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002170:Canada; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004341:Drug Evaluation; D019317:Evidence-Based Medicine; D006801:Humans; D007527:Isoenzymes; D010544:Peroxidases; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D010544:Peroxidases